Repository logo
 
Publication

Central diabetes insipidus following immunization with BNT162b2 mRNA COVID-19 vaccine: a case report

2022-05Journal article Open access
Simple item page
dc.contributor.authorBouça, Bruno
dc.contributor.authorRoldão, Marisa
dc.contributor.authorBogalho, Paula
dc.contributor.authorCerqueira, Luís
dc.contributor.authorSilva-Nunes, José
dc.date.accessioned2022-05-30T10:36:33Z
dc.date.available2022-05-30T10:36:33Z
dc.date.issued2022-05
dc.description.abstractIntroduction: Cases of central diabetes insipidus (CDI) have been reported after COVID-19 infection, with hypophysitis being the most likely cause. COVID-19 vaccines' potential adverse effects may mimetize some of these complications. Case report: Woman 37 years old, with rheumatoid arthritis under adalimumab (40 mg twice a month) since December 2018. She was in her usual state of health when she received the second dose of the BNT162b2 mRNA COVID-19 vaccine (June 2021). Seven days later, she started reporting intense thirst and polyuria and consulted her family physician. Blood analysis: creatinine 0.7 mg/dL, glucose 95mg/dL, Na+ 141mEq/L, K+ 3.9 mEq/L, TSH 3.8 mcUI/L (0.38-5.33), FT4 0.9 ng/dL (0.6-1.1), cortisol 215.4 nmol/L (185-624), ACTH 21.9 pg/mL (6- 48), FSH 4.76 UI/L, LH5.62 UI/L, estradiol 323 pmol/L, IGF1 74.8 ng/mL (88-209), PRL 24.7mcg/L (3.3-26.7) osmolality 298.2 mOs/Kg (250- 325); Urine analysis: volume 10200 mL/24h, osmolality 75 mOs/Kg (300-900), density 1.002. On water restriction test: 0' - Serum osmolality 308.8mOsm/Kg vs. urine osmolality 61.0 mOsm/Kg; 60' - urine osmolality 102 mOsm/Kg; urine osmolality 1 h after desmopressine was 511mOsm/kg. MRI revealed no abnormal signs consistent with hypophysitis except for the loss of the posterior pituitary bright spot on T1 weighted imaging. Diagnosis of CDI was assumed and started therapy with desmopressine. A report of potential adverse effects was addressed to national health authorities. Conclusion: In hypophysitis, MRI often shows loss of posterior pituitary bright spot on T1 weighted imaging, pituitary enlargement, or stalk thickening but those findings were not present in this patient. To the best of our knowledge, CDI has never been reported following the administration of a COVID-19 vaccine.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationBouça B, Roldão M, Bogalho P, Cerqueira L, Silva-Nunes J. Central diabetes insipidus following immunization with BNT162b2 mRNA COVID-19 vaccine: a case report. Front Endocrinol. 2022;13:889074.pt_PT
dc.identifier.doi10.3389/fendo.2022.889074pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/14673
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherFrontiers Mediapt_PT
dc.relation.publisherversionhttps://www.frontiersin.org/articles/10.3389/fendo.2022.889074/fullpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectCOVID-19pt_PT
dc.subjectDiabetespt_PT
dc.subjectDiabetes insipiduspt_PT
dc.subjectmRNApt_PT
dc.subjectVaccinept_PT
dc.titleCentral diabetes insipidus following immunization with BNT162b2 mRNA COVID-19 vaccine: a case reportpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.startPage889074pt_PT
oaire.citation.titleFrontiers in Endocrinologypt_PT
oaire.citation.volume13pt_PT
person.familyNameSilva-Nunes
person.givenNameJosé António
person.identifier.ciencia-id4B1C-E132-25F0
person.identifier.orcid0000-0002-4728-1220
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication9352b380-9661-4316-ab88-6ed9be1020ac
relation.isAuthorOfPublication.latestForDiscovery9352b380-9661-4316-ab88-6ed9be1020ac

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Central diabetes insipidus following immunization with BNT162b2 mRNA COVID-19 vaccine_a case report.pdf
Size:
878.37 KB
Format:
Adobe Portable Document Format
Download

Collections

ESTeSL - Artigos